Economic assessment of adjuvant and palliative chemotherapy in colorectal cancer: A review;Évaluation économique des chimiothérapies adjuvante et palliative dans le traitement du cancer colorectal: Enseignements de la littérature

Bulletin du Cancer

Volumn 90, Issue 2, 2003, Pages 143-149

  Selke, Bernard ^a   Lebrun, Thérèse ^a   Comte, Sylvie ^b  

^a UNIVERSITÉ CATHOLIQUE DE LILLE   (France)

^b Monterre LIPHA SA   (France)

Author keywords

Chemotherapy; Colorectal cancer; Cost effectiveness; Economics

Indexed keywords

ADJUVANT THERAPY; COLORECTAL CARCINOMA; COST; ECONOMIC ASPECT; FRANCE; MEDICAL LITERATURE; MORTALITY; PALLIATIVE THERAPY; PREVALENCE; PUBLIC HEALTH; PUBLICATION; REVIEW; ADJUVANT CHEMOTHERAPY; COLORECTAL TUMOR; ECONOMICS; HUMAN; QUALITY ADJUSTED LIFE YEAR;

ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; LEVAMISOLE; QUINAZOLINE DERIVATIVE; RALTITREXED; THIOPHENE DERIVATIVE;

ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; FLUOROURACIL; FRANCE; HUMANS; LEUCOVORIN; LEVAMISOLE; PALLIATIVE CARE; QUALITY-ADJUSTED LIFE YEARS; QUINAZOLINES; THIOPHENES;

EID: 0037289673     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Schraub S, Arveux P, Mercier M, Gauthier M. Recours aux soins chirurgicaux et coût des cancers: deux études utilisant les données d'un registre de population. Rev Epidemiol Sante Publique 1996 ; 44: S33-9.
2. Koopmanschap MA, van Roijen L, Bonneux L, Barendregt JJ. Current and future costs of cancer. Eur J Cancer 1994 ; 30A: 60-5.
3. Brown ML, Riley GF, Potosky AL, Etzioni RD. Obtaining long-term disease specific costs of care: application to Medicare enrollees diagnosed with colorectal cancer. Med Care 1999 ; 37: 1249-59.
4. Borella L, Peuvrel P, Sauvage M, Maraninchi D, Philip T. Un essai d'exploitarion de la base PMSI nationale pour évaluer le volume er les modes de prise en charge du cancer en secteur hospitalier non lucratif. Rev Epidemiol Sante Publique 2000 ; 48: 53-70.
5. Selke B, Brun C, Lebrun T. Évaluation du coût du cancer colorectal en France. Gastroenterol Clin Biol 2001 ; 25: A96.
6. Canasse S. La difficile évaluation du coût du cancer colorectal en France: entretien avec B. Selke. Le Quotidien du Médecin 2001 ; 6884: 18-9.
7. Moertel CG, Fleming TR, Macdonald JS. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990 ; 322: 352-8.
8. Buyse M, Zelenluch-Jacquitte A, Chalmers TC. Adjuvant therapy of colorectal cancer: why we still don't know. JAMA 1988 ; 259 ; 3571-8.
9. Moertel CG, Fleming TR, Macdonald JS. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 1995 ; 122: 321-6.
10. Dube S, Heyen F, Jenicek M. Adjuvant chemotherapy in colorectal carcinoma: results of a meta-analysis. Dis Colon Rectum 1997 ; 40: 35-41.
11. Smith RD, Hall J, Gurney H, Harnett PR. A cost-utility approach to the use of 5-fluorouracil and levamisole as adjuvant chemotherapy for Dukes'C colonic carcinoma. Med J Austr 1993 ; 158: 319-22.
12. Brown ML, Nayfield SG, Shibley LM. Adjuvant therapy for stage III colon cancer: economics returns to research and cost-effectiveness of treatment. J Natl Cancer Inst 1994 ; 86: 424-30.
13. Bonistalli L, Bardelli F, Costantini M, Trallori G, d'Albasio G, Messori A. Adjuvant chemotherapy in patients with resectable stage III colon cancer: lifetime cost-effectiveness and cost-utility analysis. Cancer Journal 1998 ; 11: 39-47.
14. Norum J, Vonen B, Olsen JA. Adjuvant chemotherapy (5-fluorouracil and levamisole) in Dukes'B and C colorectal carcinoma: a cost-effectiveness analysis. Ann Oncol 1997 ; 8: 65-70.
15. Messori A, Bonistalli L, Costantini M, Trallori G, Tendi E. Cost effectiveness of adjuvant intraportal chemotherapy in patients with colorectal cancer. J Clin Gastroenterol 1996 ; 23: 269-74.
16. Swiss Group for Clinical Cancer Research (SAKK). Long-term results of a single course of adjuvant intraportal chemotherapy for colorectal cancer. Lanet 1995 ; 345: 349-53.
17. Glimelius B, Hoffman K, Graf W, Haglund U, Nyren O, Pahlman L, et al. Cost-effectiveness of palliative chemotherapy in advanced gastrointestinal cancer. Ann Oncol 1995 ; 6: 267-74.
18. Ferriols Lisart R, Ferriols Lisart F. Evaluacion farmacoeconomica de la asociacion del acido folinico y el 5-fluorouracilo en el tratamiento del carcinoma colorrectal avanzado. Farm Hosp 1998 ; 23: 232-40.
19. Sculpher M, Palmer MK, Heyes A. Costs incurred by patients undergoing advanced colorectal cancer therapy: a comparison of raltitexed and fluorouracil plus folinic acid. Pharmacoeconomics 2000 ; 17: 361-70.
20. Elliott R. An analysis of drug costs for the management of chemotherapy-related side effects in advanced colorectal cancer: a comparison between raltirrexed (Tomudex) and 5-fluorouracil plus folonic acid. J Oncol Pharm Practice 1996 ; 2: 186-90.
21. Summerhayes M, Wanklyn SJ, Shakespeare RA, Lovell J. Reduced pharmacy resource utilization associated with raltirrexed treatment of advanced colorectal cancer. J Oncol Pharm Practice 1997 ; 3: 24-30.
22. Kerr D, O'Connor KM. An economic comparison of the net clinical benefit and treatment costs of raltitrexed and 5-fluorouracil + leucovorin (Mayo regimen) in advanced colorectal cancer. J Drug Assessm 1999 ; 2: 295-304.
23. Ross P, Heron J, Cunningham D. Cost of treating advanced colorectal cancer: a retrospective comparison of treatment regimens. Eur J Cancer 1996 ; 32A (Suppl. 5): S13-7.
24. Groener MGH, van Ineveld BM, Byttebier G, van Hour BA, Rutten FFH. An economic evaluation of Tomudex (raltitrexed) and 5-fluorouracil plus leucovorin in advanced colorectal cancer. Anticancer Drugs 1999 ; 10: 283-8.
25. Cunningham D, Zaleberg JR, Rath U. Tomudex (ZD1694): results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia. Eur J Cancer 1995 ; 31A: 1945-54.
26. Rougier P, Van Cutsem E, Bajetta E. Phase III trial of irinotecan versus infusional fluorouracil in patients with metastatic colorectal cancer after fluorouracil failure. Lancet 1998 ; 352: 1407-12.
27. Schmitt C, Blijham G, Jolain B, Rougier P, Van Cursem E. Medical care consumption in a phase III trial comparing irinotecan with infusional 5-fluorouracil (5-FU) in patients with metastatic colorectal cancer after 5-FU failure. Anticancer Drugs 1999 ; 10: 617-23.
28. Iveson TJ, Hichish T, Schmitt C, Van Cutsem E. Irinotecan in second-line treatment of metastatic colorectal cancer: improved survival and cost-effect compared with infusional 5-FU. Eur J Cancer 1999 ; 35: 1796-804.
29. Lévy-Piedbois C, Durand-Zaleski I, Juhel H, Schmitt C, Bellanger A, Piedbois P. Cost-effectiveness of second-line treatment with irinotecan or infusional 5-fluorouracil in metastatic colorectal cancer. Ann Oncol 2000 ; 11: 157-61.
30. Trippoli S, Vaiani M, Cartel F, Messori A. Cost-effectiveness of irinotecan in advanced colorectal cancer. Ann Oncol 2000 ; 11: 899-900.
31. Douillard JY, Cunningham D, Roth AD. Irinorecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000 ; 355: 1041-7.
32. Liu G, Franssen E, Fitch M, Warner E. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997 ; 15: 110-5.
33. Twelves C, Boyer M, Findlay M, Cassidy J, Weitzel C, Barker B, et al. Capecirabine (Xeloda™) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma. Eur J Cancer 2001 ; 37: 597-604.
34. Murad AM, de Andrade CA, Delfino C, Arikian S, Doyle JJ, Dezii CM, et al. Pharmacoeconomic evaluation of tegafur-uracil (UFT) vs fluorouracil for the management of colorectal cancer in Brazil and Argentina. Clin Drug Invest 1997 ; 13: 90-8.
35. Murad AM, de Andrade CA, Delfino C, Arikian S, Doyle J, Sinha N. A pharmacoeconomic comparison of UFT and 5FU chemotherapy for colorectal cancer in South America. Ontology 1997 ; 9 (Suppl 10): 128-35.
36. Plate S. Stage IV human colon cancer chemotherapy with ftorafur and ftorafur + leucovorin: treatment results, quality of life, and cost-effectiveness. Proceedings of the Latvian Academy of Sciences 1999 ; 53: 225-30.
37. Launois R, Porrafax C, Le Lay K, Megnigbeto A, Perrocheau G. Internet pharmaco-economic studies in metastatic colorectal cancer. Crit Rev Oncol Hematol 2001 ; 38: 63-77.
38. Lokich JJ, Moore CL, Anderson NR. Comparison of costs for infusion versus bolus chemotherapy administration: analysis of five standard chemotherapy regimens in three common tumors (part one). Cancer 1996 ; 78: 294-9.
39. Lokich JJ, Moore CL, Anderson NR. Comparison of costs for infusion versus bolus chemotherapy administrations (part two). Cancer 1996 ; 78: 300-3.
40. Durand-Zaleski I, Roche B, Buyse M, Carlson R, O'Connell M, Rougier P, et al. Economic implications of hepatic arterial infusion versus intravenous chemotherapy or symptom palliation in the treatment of nonresectable colorectal liver metastases. Crit Rev Oncol Hematol 1999 ; 32: 125-31.